Sign In
Buy CVAC
$4.66
+0 (+0%)
At Close: Apr 02, 2026
A flurry of announcements relating to COVID vaccines dominated headlines on the pandemic on Monday, with Moderna telling investors it expects to generate some $5 billion in sales in 2023.
CureVac shares surge after preliminary data on COVID-19 and flu shots
05:21am, Monday, 09'th Jan 2023
CureVac CVAC, +29.47% shares rocketed 26% in premarket trade as the German company said preliminary data from its early stage trial for its COVID-19 and seasonal flu shots had positive results to adva
CureVac (CVAC) Stock Rises 25% on Positive Data for Covid-19 and Flu Vaccines
03:09pm, Friday, 06'th Jan 2023
Amid a strong showing on Wall Street prior to the weekend, shares of CureVac (NASDAQ: CVAC ) stock popped dramatically northward on positive data for its coronavirus and flu vaccines. Preliminary clin
CureVac N.V. (CVAC) Q3 2022 Earnings Call Transcript
04:33pm, Wednesday, 16'th Nov 2022
Start Time: 09:00 January 1, 0000 10:01 AM ET CureVac N.V. (NASDAQ:CVAC ) Q3 2022 Earnings Conference Call November 16, 2022, 09:00 AM ET Company Participants Franz-Werner Haas - CEO Pierre Kemula - C
CureVac to Report Third Quarter and First Nine Months 2022 Financial Results and Business Updates on November 16, 2022
07:15am, Thursday, 10'th Nov 2022
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / November 10, 2022 / CureVac N.V. (NASDAQ:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribon
Bet on These 4 Biotech Stocks With Bright Prospects
10:32am, Wednesday, 28'th Sep 2022
New drug approvals and pipeline development should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position AGEN, CVAC, IMCR and DVAX well am
Jim Cramer's 'dirty dozen' stocks that underscore the carnage in the IPO market
06:46pm, Tuesday, 27'th Sep 2022
This year's market downturn has hit the IPO market hard.
CureVac is focusing on mRNA cancer vaccines, CFO says
06:46am, Tuesday, 20'th Sep 2022
Pierre Kemula, CureVac CFO, discusses the future of the technology.
Here's Why CureVac N.V. (CVAC) is Poised for a Turnaround After Losing 20.9% in 4 Weeks
12:03pm, Monday, 29'th Aug 2022
CureVac N.V. (CVAC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it.
BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims
11:59am, Tuesday, 26'th Jul 2022
COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. pate
Wall Street Analysts Predict a 96% Upside in CureVac N.V. (CVAC): Here's What You Should Know
11:36am, Monday, 11'th Jul 2022
The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 96.4% upside in the stock.
BioNTech sued by CureVac over its mRNA technology
09:46am, Wednesday, 06'th Jul 2022
CureVac (NASDAQ:CVAC) has filed a patent lawsuit in Germany against BioNTech (NASDAQ:BNTX) in what is one of the first court cases in which a company has sued another for using mRNA technology in d
CureVac Files COVID-19 Vaccine Patent Infringement Lawsuit Against BioNTech
09:36am, Tuesday, 05'th Jul 2022
CureVac N.V. (NASDAQ: CVAC) has moved to assert its intellectual property rights, accumulated over two decades of pioneering work in mRNA technology, which contributed to COVID-19 vaccine developmen
CureVac Sues BioNTech Over mRNA and Covid Vaccines. Pfizer Stock Isn't Spared.
07:46am, Tuesday, 05'th Jul 2022
CureVac says its intellectual property portfolio protects multiple inventions that are considered essential to Pfizer and BioNTech's Covid-19 vaccine.
BioNTech stock falls after CureVac files suit, saying COVID vaccine infringes patents
07:35am, Tuesday, 05'th Jul 2022
Shares of BioNTech SE BNTX, +5.63% fell 0.9% in premarket trading Tuesday, after CureVac N.V. CVAC, +4.63% filed in Germany a patent infringement suit against the biotechnology company.
